about
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsResults of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaFeasibility of therapy with hypomethylating agents in patients with renal insufficiencyOvercoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateImatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.DNA methylation patterns at relapse in adult acute lymphocytic leukemia.DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia.Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemThe effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersRecent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyMaintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.Clinical effect of point mutations in myelodysplastic syndromesMyeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemPhase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyAzacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
P50
Q24648438-6F16E21F-4461-40C7-92D6-537EF5B16D66Q27851450-D55E648D-B4D4-4943-84B3-4FC89BD1F830Q27851467-73137AD2-2607-43D0-970A-1A5B5CA83AEDQ28189439-341A5B4F-8830-4A74-B6B1-1EFE14FD1D40Q28283836-3EEF42F1-F049-4789-AD4C-3EE23F8DC099Q28383320-9A80B86D-299A-4FC1-9DE9-735CAD1FBD58Q30885947-6F482E43-E03F-4A1F-B43A-186B9CFDA77FQ33183805-53FC4E90-9DE5-4428-A087-B6831C404BBAQ33183927-C0A3B063-C83C-4024-8A52-415F65CC474EQ33185818-415E228B-A7EC-4A85-94E4-661D2B32EE64Q33186068-32EA7DE8-A2BE-4A8E-9AB4-A85F4F067BC6Q33343726-791EBB01-CF75-4D43-8BFA-29D4AF73CD47Q33358646-87342F8B-461F-4217-8AF6-62FA535FF33DQ33360707-20176B0E-8FDD-431F-BF9D-38745ECC29E8Q33366045-226B7AB9-4916-4B42-B797-419E6A83C66CQ33366921-D486A1A7-BDA2-49DD-B552-2A6714F7DF90Q33372218-E3BDF062-4BFC-436E-A580-BDC17F25A6DAQ33376638-5F7D1ADC-F90D-492E-9FEF-85A1209BB7CEQ33380307-7E6F6B38-98DD-49A3-BDAE-A3D06C9ACC9FQ33380383-477223A8-C6A6-4837-90E5-FF7F96F57993Q33381378-20092F49-BCFE-4EA5-9D58-25579254357DQ33384181-DCDCEB57-34F4-4CE5-830A-D4C2492E7ECBQ33386057-3A5C7338-3326-4BD6-8A3A-AC89A2BB8454Q33387514-5D44447B-2D23-4D8E-8427-0E618D7FCCCCQ33390778-1F87349F-7BB5-45AF-9595-66A0A88B140FQ33391089-A0F39CCD-27A7-4019-B4F1-CCF5A94DC3F7Q33391237-9A993D0B-AF5D-49B6-BD1A-4C97598EB22BQ33392185-F1210E4B-4D24-46BC-B575-97E3AB28B293Q33393647-62731F54-02AA-4934-AFD3-EAD9E2A6A1CFQ33395333-C2F3F6D3-BE60-4843-AA39-D48D2125C885Q33395996-85A442F1-9984-48DD-A639-D0212490DD01Q33397876-A9D24BA1-226A-4622-8D14-CED30C5AD221Q33399233-CC5C88AB-7BEB-4CCC-88BC-EADA0A445B34Q33401001-A307AF7E-DB7F-4A76-AA0E-5C9A7084442CQ33402882-11009B43-F797-4956-8C22-91F651F67565Q33403865-9401875F-664D-4083-A99E-CB6301050F20Q33404975-08AF5F72-AE70-40A9-A93E-5F32F8CECE88Q33407572-77B11526-92F9-492B-801C-763931721CC4Q33408184-D88D25C9-D2E4-4E9F-8B0E-A5083B0D5F1BQ33430655-781F34E1-B2C4-4DF6-929D-74F712DB6686
P50
name
Guillermo Garcia-Manero
@ast
Guillermo Garcia-Manero
@en
Guillermo Garcia-Manero
@nl
type
label
Guillermo Garcia-Manero
@ast
Guillermo Garcia-Manero
@en
Guillermo Garcia-Manero
@nl
prefLabel
Guillermo Garcia-Manero
@ast
Guillermo Garcia-Manero
@en
Guillermo Garcia-Manero
@nl